Skip to main content
Journal ArticleOPEN ACCESS

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status

Clinical Case Reports (2021) 9(4) 2007-2010
DOI: 10.1002/ccr3.3927
3Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Lorlatinib treatment should be positively considered even for patients with ALK-positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis.

Author supplied keywords

Cite

CITATION STYLE

APA

Taketa, T., & Nakamura, T. (2021). Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status. Clinical Case Reports, 9(4), 2007–2010. https://doi.org/10.1002/ccr3.3927

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free